DRUG M16-438 - A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-Tumor Activity of ABBV-321 in Subjects with Advanced Solid Tumors Associated with Overexpression of the Epidermal Growth Factor Receptor (EGFR) or its Ligands

Project: Research project

StatusActive
Effective start/end date10/18/1910/18/22

Funding

  • AbbVie Inc. (DRUG M16-438)